Skip to main content
Year archive

Alligator Bioscience — 2020 filings

All 72 regulatory filings released by Alligator Bioscience (ATORX) in 2020, sourced directly from the official regulator.

72 Filings
2020 Period
2020 filings (72)
Filing Released Lang
Alligator Bioscience offentliggör prospekt med anledning av förestående företrädesemission
Capital/Financing Update
2020-12-30 Swedish
Alligator Bioscience publishes prospectus in connection with forthcoming rights issue
Capital/Financing Update
2020-12-30 English
Alligator Bioscience utser ny Chief Medical Officer
Board/Management Information
2020-12-29 Swedish
Alligator Bioscience recruits new Chief Medical Officer
Board/Management Information
2020-12-29 English
Alligator Bioscience submits CTA for the mitazalimab Phase II study OPTIMIZE-1
Regulatory Filings
2020-12-28 English
Alligator Bioscience lämnar in CTA-ansökan för mitazalimabs fas II-studie OPTIMIZE-1
Regulatory Filings
2020-12-28 Swedish
Alligator genomför en fullt garanterad företrädesemission om cirka 86 MSEK
Capital/Financing Update
2020-12-15 Swedish
Alligator carries out a fully guaranteed rights issue of approximately SEK 86m
Capital/Financing Update
2020-12-15 English
Alligator Bioscience launches ALLIGATOR-FAB™ – a novel human antibody library
Regulatory Filings
2020-12-10 English
Alligator Bioscience presenterar ALLIGATOR-FAB™ - ett nytt antikroppsbibliotek
Regulatory Filings
2020-12-10 Swedish
Godkänd IND för Alligator Biosciences CD40-antikropp mitazalimab
Regulatory Filings
2020-12-04 Swedish
Approved IND for Alligator Bioscience’s CD40-targeting antibody mitazalimab
Regulatory Filings
2020-12-04 English
Nomination Committee appointed in respect of AGM 2021 in Alligator Bioscience AB
Board/Management Information
2020-11-20 English
Valberedning utsedd inför årsstämma 2021 i Alligator Bioscience AB
AGM Information
2020-11-20 Swedish
Alligator Bioscience och Aptevo Therapeutics förbereder den bispecifika 4-1BBx5T4-antikroppen ALG.APV-527 för klinisk fas I
Regulatory Filings
2020-11-16 Swedish
Aptevo Therapeutics and Alligator Bioscience advancing the bispecific 4-1BBx5T4 antibody ALG.APV-527 into Phase I clinical development
Regulatory Filings
2020-11-16 English
Alligator Bioscience presenterar på SITC 35th Annual Meeting
Regulatory Filings
2020-11-09 Swedish
Alligator Bioscience presents at the SITC 35th Annual Meeting
AGM Information
2020-11-09 English
Alligator Bioscience presenterar mitazalimab på World Immunotherapy Congress 2020
Regulatory Filings
2020-11-05 Swedish
Alligator Bioscience presents the CD40 antibody mitazalimab at the World Immunotherapy Congress 2020
Regulatory Filings
2020-11-05 English
Förväntat terapeutiska dosnivåer uppnådda i fas I-studie med ATOR-1017
Regulatory Filings
2020-10-27 Swedish
Predicted therapeutic range dose levels reached in ATOR-1017 Phase I
Regulatory Filings
2020-10-27 English
Interim / Quarterly Report 2020
Interim / Quarterly Report 9M 2020
2020-10-22 Swedish
Interim / Quarterly Report 2020
Interim / Quarterly Report 9M 2020
2020-10-22 English
Alligator Bioscience focuses on ATOR-1017 and mitazalimab
Regulatory Filings
2020-10-22 English
Alligator Bioscience fokuserar på ATOR-1017 och mitazalimab
Report Publication Announcement
2020-10-22 Swedish
Alligator Bioscience utser Gayle Mills till Chief Business Officer
Board/Management Information
2020-09-28 Swedish
Alligator Bioscience appoints Gayle Mills as Chief Business Officer
Board/Management Information
2020-09-28 English
Alligator Bioscience lanserar ett nytt immunonkologikoncept
Regulatory Filings
2020-09-24 Swedish
Alligator Bioscience launches a new immuno-oncology concept
Regulatory Filings
2020-09-24 English
Alligator Bioscience erhåller patent för läkemedelskandidaten ATOR-1015
Regulatory Filings
2020-09-16 Swedish
Alligator Bioscience receives patent approval for the drug candidate ATOR-1015
Regulatory Filings
2020-09-16 English
Alligator Bioscience ger en uppdatering gällande fas I-studien med läkemedelskandidaten ATOR-1015
Regulatory Filings
2020-09-09 Swedish
Alligator Bioscience presents an update regarding the Phase I study with the drug candidate ATOR-1015
Regulatory Filings
2020-09-09 English
Alligator Bioscience presents positive biomarker data demonstrating proof of mechanism in mitazalimab clinical Phase I study
Regulatory Filings
2020-09-04 English
Alligator Bioscience presenterar positiva biomarkördata från klinisk fas I-studie som bekräftar mitazalimabs verkningsmekanism
Regulatory Filings
2020-09-04 Swedish
Alligator Bioscience: Encouraging interim safety data in ATOR-1017 clinical Phase I study
Earnings Release FY 2020
2020-08-27 English
Alligator Bioscience: Lovande säkerhetsdata i klinisk fas I-studie med ATOR-1017
Regulatory Filings
2020-08-27 Swedish
Alligator Bioscience presents the clinical project portfolio at Virtual R&D Day August 27, 2020
Investor Presentation
2020-08-25 English
Alligator Bioscience presenterar den kliniska projektportföljen vid virtuell FoU-dag den 27 augusti 2020
Regulatory Filings
2020-08-25 Swedish
Interim / Quarterly Report 2020
Interim / Quarterly Report H1 2020
2020-07-13 Swedish
Interim / Quarterly Report 2020
Interim / Quarterly Report H1 2020
2020-07-13 English
Alligator Bioscience erhåller det första patentet för ATOR-1017
Regulatory Filings
2020-06-23 Swedish
Alligator Bioscience receives first patent approval for ATOR-1017
Investor Presentation
2020-06-23 English
Alligator Bioscience appoints new CFO
Board/Management Information
2020-06-15 English
Alligator Bioscience utser ny CFO
Board/Management Information
2020-06-15 Swedish
Aptevo Therapeutics and Alligator Bioscience present new preclinical data for ALG.APV-527 at the PEGS Virtual Interactive Global Summit
Regulatory Filings
2020-06-10 English
Aptevo Therapeutics och Alligator Bioscience presenterar nya prekliniska data för ALG.APV-527 på PEGS Virtual Interactive Global Summit
Regulatory Filings
2020-06-10 Swedish
Alligator Bioscience and Scandion Oncology sign preclinical agreement to explore combination therapies for chemotherapy and immuno-oncology
Regulatory Filings
2020-06-04 English
Alligator Bioscience och Scandion Oncology tecknar prekliniskt samarbetsavtal för utvärdering av cellgiftsbehandling i kombination med immunonkologi
Regulatory Filings
2020-06-04 Swedish
Alligator Biosciences samarbete med Biotheus Inc. går vidare med en andra delbetalning
Capital/Financing Update
2020-06-01 Swedish
Alligator Bioscience’s collaboration with Biotheus Inc. proceeds and second payment is received
Capital/Financing Update
2020-06-01 English
Alligator Bioscience presenterar ATOR-1015 på ASCO: Ytterligare positiva fas I-data för den bispecifika CTLA-4 x OX40-antikroppen
Investor Presentation
2020-05-29 Swedish
Alligator Bioscience presents novel supportive Phase I data at ASCO for its CTLA-4 x OX40 bispecific drug candidate ATOR-1015
Regulatory Filings
2020-05-29 English
Kommuniké från årsstämma den 5 maj 2020 i Alligator Bioscience AB
AGM Information
2020-05-05 Swedish
Bulletin from the annual general meeting in Alligator Bioscience AB on May 5, 2020
AGM Information
2020-05-05 English
Alligator Bioscience presents promising interim Phase I data for its bispecific drug candidate ATOR-1015 at AACR
Earnings Release FY 2020
2020-04-27 English
Alligator Bioscience presenterar lovande interimsdata i fas I för sin bispecifika läkemedelskandidat ATOR-1015 på AACR
Investor Presentation
2020-04-27 Swedish
Interim / Quarterly Report 2020
Interim / Quarterly Report Q1 2020
2020-04-23 Swedish
Interim / Quarterly Report 2020
Interim / Quarterly Report Q1 2020
2020-04-23 English
Alligator Bioscience's Board of Directors reduces its fees and offers possibility for postal voting in front of the Annual General Meeting
AGM Information
2020-04-20 English
Alligator Biosciences styrelse sänker sina arvoden och erbjuder möjlighet till poströstning inför årsstämman
AGM Information
2020-04-20 Swedish
Alligator Bioscience ökar fokus på sin kliniska utveckling
Regulatory Filings
2020-04-07 Swedish
Alligator Bioscience increases focus on clinical development
Regulatory Filings
2020-04-07 English
Kallelse till årsstämma i Alligator Bioscience AB (publ)
AGM Information
2020-04-01 Swedish
Notice of annual general meeting in Alligator Bioscience AB (publ)
AGM Information
2020-04-01 English
Alligator Bioscience informs about temporary halt of recruitment of new patients due to the covid-19 pandemic
Regulatory Filings
2020-04-01 English
Alligator Bioscience informerar om tillfälligt uppehåll i rekrytering av nya patienter som följd av covid-19-pandemin
Regulatory Filings
2020-04-01 Swedish
Annual Report 2019
Annual Report FY 2019
2020-03-02 Swedish
Annual Report 2019
Annual Report FY 2019
2020-03-02 English
Interim / Quarterly Report 2019
Interim / Quarterly Report Q4 2019
2020-02-12 Swedish
Interim / Quarterly Report 2019
Interim / Quarterly Report Q4 2019
2020-02-12 English